圣湘生物(688289) - 2021 Q1 - 季度财报

Financial Performance - Operating income surged by 191.01% to CNY 1,162,834,697.42 year-on-year[18] - Net profit attributable to shareholders rose by 222.21% to CNY 622,104,937.78 compared to the same period last year[18] - Basic earnings per share reached CNY 1.56, up 188.89% from CNY 0.54 in the previous year[21] - The company reported a total net profit after deducting non-recurring gains and losses of CNY 593,952,660.99, an increase of 209.63% year-on-year[18] - The company's revenue for Q1 2021 reached ¥1,162,834,697.42, a 191.01% increase compared to ¥399,583,498.49 in Q1 2020, primarily driven by significant sales growth in COVID-related and regular products[34] - The net profit for the first quarter of 2021 was CNY 623,900,849.90, a significant increase from CNY 188,206,274.02 in the same period of 2020, representing a growth of approximately 231.5%[66] - The total operating income for the first quarter of 2021 reached CNY 735,108,059.26, compared to CNY 223,926,216.90 in Q1 2020, indicating an increase of about 228.5%[66] Cash Flow - Net cash flow from operating activities increased by 106.66% to CNY 307,312,501.65 year-on-year[18] - The cash inflow from operating activities amounted to CNY 1,055,125,634.55, up from CNY 328,368,051.18 in Q1 2020, reflecting a growth of approximately 221.5%[66] - The cash flow from financing activities resulted in a net outflow of CNY 41,685,749.67 in Q1 2021, contrasting with a net inflow of CNY 33,713,666.67 in Q1 2020[72] - The company’s cash and cash equivalents at the end of Q1 2021 were CNY 2,506,195,255.07, down from CNY 170,407,695.82 at the end of Q1 2020, reflecting a decrease of approximately 1,373.5%[72] - The cash flow from operating activities showed a strong performance with a total outflow of $755,624,097.91, highlighting the company's operational scale[76] Assets and Liabilities - Total assets increased by 14.24% to CNY 6,231,125,849.05 compared to the end of the previous year[18] - The company's inventory increased by 79.06% to ¥495,523,912.91 as of March 31, 2021, compared to ¥276,735,617.47 at the end of 2020, due to stockpiling for COVID-related products[34] - Current liabilities rose to ¥810,775,057.01 compared to ¥688,688,838.85, an increase of about 17.7%[44] - Total liabilities increased to ¥863,586,585.44 from ¥708,949,114.95, representing a growth of about 22.0%[44] - The company's equity attributable to shareholders rose to ¥5,367,539,263.61 from ¥4,745,425,022.72, an increase of approximately 13.1%[44] Research and Development - Research and development expenses accounted for 1.91% of operating income, a decrease of 0.60 percentage points compared to the previous year[21] - Research and development expenses rose by 120.83% to ¥22,185,593.10 in Q1 2021, compared to ¥10,046,293.55 in Q1 2020, reflecting increased investment in personnel and other inputs[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,104[24] - The largest shareholder, Dai Lizhong, holds 31.62% of the shares, totaling 126,488,642 shares[24] Investment Activities - The company acquired investment properties worth ¥82,650,636.95 during the reporting period, contributing to its asset growth[34] - The cash outflow from investing activities was CNY 1,675,245,608.18 in Q1 2021, compared to CNY 132,506,572.41 in Q1 2020, indicating a significant increase in investment activities[70] - Cash paid for investments totaled $1,640,015,858.10, indicating aggressive investment strategies[76]